Wedbush Maintains Outperform Rating on Disc Medicine, $110 Target
Wedbush maintained its Outperform rating and $110 price target on Disc Medicine.
Story updates
12:45:02 PM UTC
SquawkNews
Ratings actions from Benzinga: GMT) Disc Medicine Price Target Raised to $110.00/Share From $100.00 by WedbushRatings actions from Benzinga